Status:
COMPLETED
Treatment Strategy to Enhance Nrf2 Signaling in Older Adults
Lead Sponsor:
Northern Arizona University
Collaborating Sponsors:
Villanova University
Conditions:
Aging Problems
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
Exercise is the cornerstone of disease prevention and often an important component of treatment. However, the efficacy of an exercise stimulus is reduced with aging. This study will investigate whethe...
Detailed Description
Redox balance plays a key role in the age-associated increased risk for diseases. One reason for the lower resistance to oxidative stress with age is a gradual shift in the redox state toward a more o...
Eligibility Criteria
Inclusion
- Men and women, 60 years and older
- Competent to independently give informed consent
- Successful completion of screening
- Maximal oxygen consumption below the 60th percentile based on gender:
- Women: ≤ 21.2 mL/kg/min
- Men: ≤ 30.5 mL/kg/min
Exclusion
- Estrogen supplementation (in any form) within the previous 6 months
- Any medication that could affect outcome measures such as statins, blood pressure medications, or anti-depressives
- Use of anti-oxidant supplements, in excess of standard multi-vitamins (1 tablet/day) and/or any supplements known to target Nrf2 including resveratrol, Protandim, and sulforaphane
- Current smoker
- Body Mass Index (BMI) greater than 33 kg/m2 (Class I Obesity)
- Any chronic illness that could affect outcome measures, including diabetes, liver or renal disease, or cancer (other than skin cancer)
- History of a myocardial infarction within the last 6 months, clinically significant aortic stenosis, use of cardiac defibrillator, or uncontrolled angina
- Clinically significant arrhythmia on a resting EKG or significant EKG changes during the baseline VO2 max test
- Any other condition that would contraindicate maximal exercise testing, including elevated blood pressure at rest (systolic BP \>150 or diastolic BP \>90 mm Hg on at least 2 measurements, at least 10 minutes apart) or musculoskeletal problems
Key Trial Info
Start Date :
February 9 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 27 2025
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04848792
Start Date
February 9 2023
End Date
May 27 2025
Last Update
August 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northern Arizona University
Flagstaff, Arizona, United States, 86011